The FDA has approved MannKind’s AFREZZA® (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes mellitus. “Today’s FDA action validates the years of clinical research and commitment that powered the development of this unique therapy,” said Alfred Mann, Chief Executive Officer of the company.

press release
article in BloombergBusinessweek